Long-Term Efficacy of Risk-Directed, De-Escalated Post-Operative Adjuvant Therapy for Surgically Resected Locally Advanced, Human Papillomavirus-Positive Oropharynx Squamous-Cell Carcinoma (HPV+ OPSCC): A Non-Randomized, Multi-Arm Phase 2 TrialWade L. Thorstad, D. Adkins, Jason T. Rich et al.|International Journal of Radiation Oncology*Biology*Physics|2024Cited by 5
Acute Toxicity Profile and Early Efficacy Results of De-Escalated, Risk-Directed Post-Operative Adjuvant Therapy for Human Papillomavirus-Positive Oropharynx Squamous-Cell Carcinoma: A Phase 2 TrialZ. Jose, Douglas R. Adkins, Wade L. Thorstad et al.|International Journal of Radiation Oncology*Biology*Physics|2022Cited by 1